Evidence map›Paper›PMID 29691438›Full record

ArticleScientific reports2018

The Hippo Signaling Transducer TAZ Regulates Mammary Gland Morphogenesis and Carcinogen-induced Mammary Tumorigenesis.

Kayla E Denson, Ashley L Mussell, He Shen, Alexander Truskinovsky, Nuo Yang, Natesh Parashurama, Yanmin Chen, Costa Frangou, Fajun Yang, Jianmin Zhang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Kayla E DensonDepartment of Cancer Genetics & Genomics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
Ashley L MussellDepartment of Cancer Genetics & Genomics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
He ShenDepartment of Cancer Genetics & Genomics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
Alexander TruskinovskyDepartment of Pathology, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
Nuo YangDepartment of Anesthesiology, University at Buffalo, The State University of New York, NY, 14214, USA.
Natesh ParashuramaDepartment of Chemical & Biological Engineering, University at Buffalo, The State University of New York, NY, 14214, USA.
Yanmin ChenDepartment of Cancer Genetics & Genomics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA.
Costa FrangouHarvard TH Chan School of Public Health, Molecular and Integrative Physiological Sciences, 665 Huntington Avenue, Boston, MA, 02115, USA.
Fajun YangDepartments of Medicine, Diabetes Research Center, Albert Einstein College of Medicine, Bronx, NY, 10461, USA.
Jianmin ZhangDepartment of Cancer Genetics & Genomics, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA. Jianmin.zhang@roswellpark.org.
Roswell Park Comprehensive Cancer Center · USCancer Genetics (United States) · USUniversity at Buffalo, State University of New York · USAlbert Einstein College of Medicine · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
The role of TAZ in breast cancer initiation and progressionR01CA207504 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ZHANG, JIANMIN · 2017 to 2021
$2.0M
Hippo signaling pathway in breast cancer disparities: a translational approachR21CA179693 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ZHANG, JIANMIN · 2014 to 2015
$615k
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA207504NCI NIH HHS R21 CA179693
6 · The paper itself

Abstract

Hippo signaling pathway is an evolutionarily conserved pathway that controls organ size by regulating cell proliferation, apoptosis and stem cell self-renewal. TAZ (transcriptional coactivator with the PDZ-binding motif) is a key downstream effector of the mammalian Hippo pathway. Here, using a transgenic mouse model with mammary-gland-specific expression of constitutively active TAZ, we found that TAZ induction in mammary epithelial cells was associated with an increase in mammary glandular size, which probably resulted from adipocyte hypertrophy. Consistent with its known oncogenic potential, we observed tumor formation in TAZ transgenic mice after administration of the carcinogen 7,12-dimethylbenzanthracene (DMBA) and demonstrated that tumorigenesis was reliant on the presence of TAZ. Our findings establish a previously unknown roles of TAZ in regulating both mammary gland morphogenesis as well as carcinogen-induced mammary tumor formation.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsApoptosisCarcinogenesisCell ProliferationCell Transformation, NeoplasticEpithelial CellsFemaleHippo Signaling PathwayHumansIntracellular Signaling Peptides and ProteinsMammary Glands, AnimalMammary Neoplasms, AnimalMiceMice, Inbred C57BLMice, TransgenicAdaptor Proteins, Signal TransducingIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine KinasesTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsWWTR1 protein, humanWwtr1 protein, mouse

Identifiers

PMID29691438
PMCPMC5915420
OpenAlexW2806142051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.